Mounjaro price guide in Japan
How to compare medication price, consultation fees, delivery fees and long-plan conditions.
In Japan, Mounjaro (tirzepatide) is approved for type 2 diabetes. Use for weight management is off-label and requires individual medical assessment, risk explanation, and a prescribing decision. Dose is based on medical history, prior use, response, adverse effects, and concomitant medicines.
Primary source: PMDA prescribing information
A comprehensive English hub for Mounjaro (tirzepatide) 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg and 15mg, covering dose positioning, prices, side effects, online consultation, pharmacy counseling, delivery and detailed related articles.
Escalation is not automatic. If the current dose is effective and tolerated, it may be continued.
In Japan, Mounjaro is approved for type 2 diabetes. Use for weight management in private care is off-label.
Common starting dose used to assess tolerability.
Usual maintenance dose considered after four weeks at 2.5mg.
Intermediate step considered after at least four weeks when 5mg is insufficient.
Higher dose considered when 7.5mg remains insufficient and tolerability is acceptable.
May be considered when 10mg remains insufficient and tolerability is acceptable.
The maximum dose, considered cautiously when 12.5mg remains insufficient and tolerability is acceptable.
Escalation is not automatic. If the current dose is effective and tolerated, it may be continued.
| Dose | 1 month | 3 months | 6 months |
|---|---|---|---|
| 2.5mg | ¥11,800 | ¥31,800 | ¥61,800 |
| 5mg | ¥18,800 | ¥51,800 | ¥99,800 |
| 7.5mg | ¥29,800 | ¥79,800 | ¥144,800 |
| 10mg | ¥37,800 | ¥97,800 | ¥179,800 |
| 12.5mg | ¥46,800 | ¥124,800 | ¥239,800 |
| 15mg | ¥54,800 | ¥146,800 | ¥279,800 |
SURMOUNT-1 was a 72-week trial in adults with obesity or overweight without diabetes. Mean body-weight change in the 10mg group was −19.5%. This was a controlled trial with defined participants, lifestyle intervention and follow-up, and it does not predict an individual result.
The chart visualizes group means reported in the paper. It does not predict an individual response at each dose.
The SURPASS program also evaluated tirzepatide doses including 10mg in people with type 2 diabetes. Obesity and diabetes trials have different populations and objectives, so their results should not be treated as interchangeable.
Common adverse effects include nausea, vomiting, diarrhea, constipation, abdominal discomfort and reduced appetite. Gastrointestinal events are reported more often during dose escalation.
AURELIA ONLINE uses an outside-pharmacy model. The medical consultation and prescribing decision are handled by Chiaro Clinic, while dispensing and pharmacist counselling are handled by a partner pharmacy. For that reason, payment can be split between the clinic and the pharmacy. To make comparison easier, the public price table shows the combined tax-included total. It is not an automatic subscription; dose and continuation are reviewed at each consultation.
Usually used to start treatment and assess gastrointestinal tolerability before moving to 5 mg.
If response is adequate, there is no requirement to move higher simply because higher strengths exist.
Considered after adequate time on 5 mg when response remains insufficient and tolerability is acceptable.
Higher doses are not a goal in themselves. Dose choice should balance benefit, adverse effects, weight and glucose control.
A complete high-dose cluster covering escalation, side effects, plateau, long-term maintenance, dose reduction and prices in Japan.
The goal is not to reach the maximum dose; it is to use the dose that best balances benefit, tolerability and long-term safety.
How to compare medication price, consultation fees, delivery fees and long-plan conditions.
When continuing 7.5mg may be reasonable and when 10mg may be considered.
Key checks before escalation: duration, response, adverse effects and medical review.
Nausea, constipation, diarrhea, vomiting and signs that need medical attention.
How diet, activity, sleep, constipation and fluid shifts affect apparent response.
Why restart dose depends on the treatment gap, previous dose and adverse effects.
Considerations for pregnancy planning, pregnancy and breastfeeding.
Practical guidance on protein intake and resistance training during weight loss.
How to choose meals when appetite and portion size are reduced.
Ways to secure protein and fluids with smaller meals.
After prescribing, the partner pharmacy provides counselling and payment instructions, followed by delivery or the agreed pickup method.
The current public price is shown as a combined tax-included total of consultation and medication. Delivery fees may be separate.
Because the clinic provides the medical consultation/prescribing decision and the partner pharmacy provides dispensing and pharmacist counselling. The website shows the combined total for clarity.
A short plateau does not automatically mean treatment failure. Review bowel habits, food intake, activity, treatment duration and the overall amount already lost.
Large weight loss can include some lean mass. Adequate nutrition, protein and resistance exercise are important when appropriate.
Mounjaro should not be used during pregnancy. Discuss planned pregnancy with the prescribing doctor in advance.
No specific approved injection site is expected to produce greater weight loss. Correct technique and site rotation matter.
No. These are higher-dose options reached stepwise when medically appropriate. 15 mg is the maximum weekly dose.
After adequate time at the preceding dose when response is insufficient and adverse effects are acceptable.
No. If 5 mg is working well, escalation may not be necessary.
It is the usual starting dose. The first weeks are used to assess tolerability before the standard move to 5 mg.
No. Treatment continuation and dose are reviewed at each consultation.
In Japan, Mounjaro is approved for type 2 diabetes. Use for weight management is off-label. Individual diagnosis and prescribing decisions require a medical consultation.